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LETTER TO THE EDITOR
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Mechanical circulatory support in transcath-
eter aortic valve implantation (TAVI) procedures is 
a useful solution for both planned and in emergent 
cases and provides prophylactic implantations 
which can subsequently avoid complications. Veno-
arterial extracorporeal membrane oxygenation 
(VA-ECMO) provides both hemodynamic and 
oxygenation support. Percutaneous VA-ECMO can 
be inserted with fluoroscopy or ultrasound guid-
ance. A perfusion cannula is required to protect 
against distal limb ischemia. VA-ECMO can either 
be used in prophylactic settings or as a rescue 
therapy [1–4]. 
Reported herein, is a prophylactic VA-ECMO 
paradigm case in a TAVI setting in order to illus-
trate the main steps. Also, a systematic search of 
all existing literature was performed from the main 
bibliographic databases (Pubmed, Medline, Google 
Scholar, and Cochrane).
The case of a 63-year-old male patient with 
ischemic cardiomyopathy, severe left ventricular 
systolic dysfunction, dual-chamber implantable 
cardiac defibrillator and moderate aortic stenosis 
is presented. Two months prior to index admission, 
he developed chest pain and dyspnea at minimal 
exertion. A coronary angiogram revealed signifi-
cant stenosis of the distal left main coronary artery 
including the origin of the descendent coronary 
artery and the circumflex and the echocardiogram 
showed a severe aortic stenosis (peak velocity 
of 3.2 m/s, peak and mean gradients of 40 and 
23 mmHg respectively, estimated area of 0.9 cm2), 
functional moderate mitral regurgitation with 
effective regurgitant orifice area of 0.3 cm2, and 
left ventricular ejection fraction (LVEF) of 22%. 
A cardiac computed tomography (CT) showed an 
Agatston score of the aortic valve of 3568. Low-
flow low-gradient severe aortic stenosis diagnosis 
was made in the presence of low LVEF on the basis 
of the calcium score. Dobutamine stress echocar-
diogram was not contemplated due to coronary 
disease. Aortic-ileo-femoral axis CT revealed both 
femoral accesses above 6 mm. The Heart Team 
decided on percutaneous intervention (TAVI 
+ coronary intervention) under VA-ECMO support 
due to the high surgical risk (LogEuroScore 28%). 
A staged procedure was planned for percutaneous 
VA-ECMO implantation (CardioHelp System®, 
Maquet, Germany) via left femoral access (15 F 
arterial cannula, 23 F venous cannula) with perfu-
sion cannula (6 F) connected between the arterial 
cannula and a distal sheath in the femoral artery. It 
was programmed at 3000 rpm, with an estimated 
flow of 2.6–2.8 L/min. A bolus of 10,000 U of unfrac-
tioned heparin was given. Invasive hemodynamics 
were monitored throughout the procedure. The 
bifurcation between the left main-circumflex and 
left main-anterior descendent coronary artery was 
treated with two drug-eluting stents, finishing with 
a kissing-balloon technique. A 34 mm CoreValve 
Evolut-R (Corevalve Evolute®, Medtronic Inc., 
MN, USA) was deployed via right femoral artery, 
requiring post-dilatation with a 25 mm True Dilata-
tion Balloon (Bard Peripheral Vascular, Inc., USA). 
The cannulas were clamped sequentially and re-
moved. Femoral sites were both closed with the 
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Perclose ProGlide® suture system. There was an 
improvement in pre-discharge LVEF (around 34%). 
Femoral ultrasound confirmed no vascular compli-
cations. The patient was discharged uneventfully 
and remains asymptomatic at 6 month follow-up.  
Little has been said regarding the pro-
phylactic use of VA-ECMO before a combined 
complex TAVI and coronary procedure. Table 1 
summarizes the main studies. A series with 
14 VA-ECMO cases showed a survival rate of 50% 
in 4 cases with severe aortic valve disease [1]. 
A later series included a comparison between 
emergency versus planned ECMO in high risk 
patients, suggesting that outcomes remain bet-
ter if ECMO is implanted beforehand [2]. In this 
report, severely impaired LVEF, slow recovery 
from rapid left ventricular pacing, high vasopressor 
requirements or a concomitant high-risk percuta-
neous coronary intervention were suggested to 
be suitable scenarios for VA-ECMO prophylactic 
implantation. The rate of procedural success with 
planned ECMO in this study reached 100% with 
no evidence of 30-day mortality. In spite of such 
promising results, times of fluoroscopy were longer 
and up to 11% had vascular complications. Vascular 
complications can be inevitably seen as a concern 
in procedures requiring bilateral femoral access 
with large sheaths but can be minimized by a care-
ful selection of potential candidates, low diameter 
cannulas and percutaneous guided approach [3]. 
Eligible patients usually remain stable with a flow 
of 2 L/min and this complementary support can be 
achieved with low profile cannulas. Additionally, 
third generation TAVI devices include introducers 
of 14 F which lead to reduce vascular complications. 
In a series published by Seco et al. [4], some 
pre-procedural aspects might tip the balance for 
prophylactic ECMO, such as unstable heart failure 
pre-TAVI requiring support, hemodynamic insta-
bility after balloon aortic valvuloplasty, or poor 
baseline hemodynamic parameters. Better results 
might be obtained with prophylactic versus rescue 
implantation, despite a high risk of acute kidney 
injury (~36%) in the rescue group. For all of the 
above, the main conclusion was that results with 
a planned ECMO in a high-risk TAVI procedure is 
comparable to standard TAVI procedures [2, 4]. In 
a planned scenario, someone could argue that 
a cardiopulmonary bypass machine is cheaper, with 
less risk of bleeding complications, and avoids the 
increased afterload made by VA-ECMO by placing 
a Vent cannula. Unfortunately, it is not available 
in every hospital and cannot avoid a later VA-
ECMO implantation if coming off it is not achieved. Ta
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Regarding VA-ECMO as a rescue therapy, Ban-
jac et al. [5] report an incidence of 4.3% of TAVI 
procedures due to hemodynamic collapse, with an 
in-hospital mortality up to 30%. Even in emerging 
valve-in-valve procedures it is a feasible option for 
gaining time and deployment of the valve [6, 7]. A 
recent registry showed an incidence of mechanical 
circulatory support use of 0.6% in TAVI procedures 
with differences between elective (0.5%) and 
emergent cases (1.2%) [8]. Hemolysis and throm-
bocytopenia are recognizable complications during 
ECMO, with an increasing incidence in relation to 
time on support [9]. 
Percutaneous VA-ECMO can be seen as an 
alternative to other devices and is of great help in 
aortic stenosis scenarios [10], especially in high 
volume centres with experienced operators.  
In the current transition from surgical to per-
cutaneous treatment of aortic stenosis in more 
complex contexts, not only acceptable results in 
intermediate and low risk patients are requested but 
also in high risk once as well. There are limited data 
and few case studies supporting the use of percu-
taneous VA-ECMO in these scenarios, assuming 
a higher risk of vascular complications and obviously, 
extra costs thereby derived.
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